TY - JOUR
T1 - Progression of conventional cardiovascular risk factors and vascular disease risk in individuals
T2 - insights from the PROG-IMT consortium
AU - Bahls, Martin
AU - Lorenz, Matthias W.
AU - Dörr, Marcus
AU - Gao, Lu
AU - Kitagawa, Kazuo
AU - Tuomainen, Tomi Pekka
AU - Agewall, Stefan
AU - Berenson, Gerald
AU - Catapano, Alberico L.
AU - Norata, Giuseppe D.
AU - Bots, Michiel L.
AU - van Gilst, Wiek
AU - Asselbergs, Folkert W.
AU - Brouwers, Frank P.
AU - Uthoff, Heiko
AU - Sander, Dirk
AU - Poppert, Holger
AU - Hecht Olsen, Michael
AU - Empana, Jean Philippe
AU - Schminke, Ulf
AU - Baldassarre, Damiano
AU - Veglia, Fabrizio
AU - Franco, Oscar H.
AU - Kavousi, Maryam
AU - de Groot, Eric
AU - Mathiesen, Ellisiv B.
AU - Grigore, Liliana
AU - Polak, Joseph F.
AU - Rundek, Tatjana
AU - Stehouwer, Coen D.A.
AU - Skilton, Michael R.
AU - Hatzitolios, Apostolos I.
AU - Savopoulos, Christos
AU - Ntaios, George
AU - Plichart, Matthieu
AU - McLachlan, Stela
AU - Lind, Lars
AU - Willeit, Peter
AU - Steinmetz, Helmuth
AU - Desvarieux, Moise
AU - Ikram, M. Arfan
AU - Johnsen, Stein Harald
AU - Schmidt, Caroline
AU - Willeit, Johann
AU - Ducimetiere, Pierre
AU - Price, Jackie F.
AU - Bergström, Göran
AU - Kauhanen, Jussi
AU - Kiechl, Stefan
AU - Sitzer, Matthias
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Aims: Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thickness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for conventional risk factors is unclear. Methods and results: An individual participant meta-analysis was used to associate the annualised progression of systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with future cardiovascular disease risk in 13 prospective cohort studies of the PROG-IMT collaboration (n = 34,072). Follow-up data included information on a combined cardiovascular disease endpoint of myocardial infarction, stroke, or vascular death. In secondary analyses, annualised progression was replaced with average. Log hazard ratios per standard deviation difference were pooled across studies by a random effects meta-analysis. In primary analysis, the annualised progression of total cholesterol was marginally related to a higher cardiovascular disease risk (hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.00 to 1.07). The annualised progression of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol was not associated with future cardiovascular disease risk. In secondary analysis, average systolic blood pressure (HR 1.20 95% CI 1.11 to 1.29) and low-density lipoprotein cholesterol (HR 1.09, 95% CI 1.02 to 1.16) were related to a greater, while high-density lipoprotein cholesterol (HR 0.92, 95% CI 0.88 to 0.97) was related to a lower risk of future cardiovascular disease events. Conclusion: Averaged measurements of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol displayed significant linear relationships with the risk of future cardiovascular disease events. However, there was no clear association between the annualised progression of these conventional risk factors in individuals with the risk of future clinical endpoints.
AB - Aims: Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thickness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for conventional risk factors is unclear. Methods and results: An individual participant meta-analysis was used to associate the annualised progression of systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with future cardiovascular disease risk in 13 prospective cohort studies of the PROG-IMT collaboration (n = 34,072). Follow-up data included information on a combined cardiovascular disease endpoint of myocardial infarction, stroke, or vascular death. In secondary analyses, annualised progression was replaced with average. Log hazard ratios per standard deviation difference were pooled across studies by a random effects meta-analysis. In primary analysis, the annualised progression of total cholesterol was marginally related to a higher cardiovascular disease risk (hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.00 to 1.07). The annualised progression of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol was not associated with future cardiovascular disease risk. In secondary analysis, average systolic blood pressure (HR 1.20 95% CI 1.11 to 1.29) and low-density lipoprotein cholesterol (HR 1.09, 95% CI 1.02 to 1.16) were related to a greater, while high-density lipoprotein cholesterol (HR 0.92, 95% CI 0.88 to 0.97) was related to a lower risk of future cardiovascular disease events. Conclusion: Averaged measurements of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol displayed significant linear relationships with the risk of future cardiovascular disease events. However, there was no clear association between the annualised progression of these conventional risk factors in individuals with the risk of future clinical endpoints.
KW - CVD biomarker
KW - risk factor progression
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=85074338122&partnerID=8YFLogxK
U2 - 10.1177/2047487319877078
DO - 10.1177/2047487319877078
M3 - Article
C2 - 31619084
AN - SCOPUS:85074338122
SN - 2047-4873
VL - 27
SP - 234
EP - 243
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 3
ER -